Research

“Innovating the analysis and engineering of biomolecular systems to investigate and alleviate human disease.”

Cutting-edge biotechnology research at the CMB is directed by eight principal investigators. The research groups have a longstanding reputation in different fields of protein biology. Bringing together expertise in protein engineering and expression, interactomics, proteomics and bioinformatics enables a multi-disciplinary approach.

On a regional scale, the VIB-UGent Center for Medical Biotechnology is embedded within VIB and Ghent University, which catalyses collaborations with scientific partners.

CMB’s focus is to develop new and innovative molecular tools and technologies to challenge human health problems. An emerging and fascinating research theme at CMB is the development and production of new biopharmaceuticals and vaccines. CMB is currently working on new applications in tuberculosis research, cancer treatment, antiviral immunity and others. A strong incentive to bring CMB technologies to patients resulted in the creation of six spin-off companies; Devgen (acquired by Syngenta), Pronota (acquired by MyCartis), Oxyrane, Orionis Biosciences, Animab and Exevir.